Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  DietType 2 DiabetesPreventionIssue 647

Vitamin K1 Reduces Risk of Type 2 by 50 Percent

Adding foods or supplements rich in vitamin K1 (phylloquinone) may help protect against type 2 diabetes....
Advertisement

The study found that high intake of the vitamin can slash the risk developing type 2 diabetes in half.

The scientists report that for every 100 micrograms per day increase in the intake of vitamin K1, the risk of developing diabetes decreased by 17%.

For the analysis, N. Ibarrola-Jurado, of Universitat Rovira i Virgili in Reus, Spain, and colleagues studied data from over 1900 elderly men and women in the Prevention with the Mediterranean Diet Trial at high cardiovascular disease risk, and a further 1069 people who were free of diabetes at baseline.

Participants who increased their dietary intake of vitamin K1 during the 5-year follow-up were found to be 51 per cent less likely to develop type 2 diabetes than those who lowered or did not change their intake.

Cross-sectional associations were tested in 1925 men and women in the Prevention with the Mediterranean Diet trial. A longitudinal analysis was conducted on 1069 individuals free of diabetes at baseline (median follow-up: 5.5 y). Biochemical and anthropometric variables were obtained yearly. Dietary intake was collected during each annual visit by using a food-frequency questionnaire, and phylloquinone intake was estimated by using the USDA database. The occurrence of type 2 diabetes during follow-up was assessed by using American Diabetes Association criteria.

Dietary phylloquinone at baseline was significantly lower in subjects who developed type 2 diabetes during the study. After adjustment for potential confounders, risk of incident diabetes was 17% lower for each additional intake of 100 μg phylloquinone/d. Moreover, subjects who increased their dietary intake of vitamin K during the follow-up had a 51% reduced risk of incident diabetes compared with subjects who decreased or did not change the amount of phylloquinone intake.

The researchers concluded that "dietary phylloquinone intake is associated with reduced risk of type 2 diabetes."

Vitamin K1 is one type of the naturally occurring Vitamin K, which is found high in green vegetables including raw spinach, raw leaf lettuce, raw kale, raw Swiss chard, raw watercress, raw parsley and cooked broccoli.

First published October 3, 2012, doi: 10.3945/‚Äčajcn.111.033498 Am J Clin Nutr November 2012 ajcn.033498 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 12 October, 2012 and appeared in  DietType 2 DiabetesPreventionIssue 647

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015
Second Tuberculosis Vaccine Treatment for Type 1 Diabetes Underway
Posted June 19, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Hugh G. Calkins, MD, and Joseph Edward Marine, MD

Category: Cardiology
Credits:
 1